Anti-BCMA CAR T cells

PreclinicalCell therapy

Anti-BCMA CAR T cells is one of 2 biologic programs targeting Multiple Myeloma, Refractory. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Multiple Myeloma, RefractoryRecruiting

Multiple Myeloma, RefractoryPreclinical

Recruiting

Competition

Competitive Landscape

3 competitors in Multiple Myeloma, Refractory

#DrugCompanyPhaseTrials

HBI0101 CART

PPolina Stepensky

Phase 2

1 2

Anti-BCMA CAR T cells

HHrain Biotechnology Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2030

PreclinicalRecruiting

Multiple Myeloma, Refractory

NCT07477912

Clinical

Trials by Indication[1]

Multiple Myeloma3 trials

Study of BCMA CAR-T in Multiple Myeloma

Unknown status·AAllife Medical Science and Technology Co., Ltd.·Phase 1·NCT03559764·20 enrolled

BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma

Unknown status·HHrain Biotechnology Co., Ltd.·Phase 1·NCT03943472·10 enrolled

BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma

Unknown status·TThe Second Affiliated Hospital of Henan University of Traditional Chinese Medicine·Phase 1·NCT03093168·10 enrolled

Multiple Myeloma, Refractory1 trial

Phase I/II Open-label Study Evaluating The Safety And Efficacy of Anti BCMA CAR-T Cell Therapy in Adults With R/ R Multiple Myeloma

Recruiting·MMinsk Scientific-Practical Center for Surgery, Transplantation and Hematology·Preclinical·NCT07477912·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Anti-BCMA CAR T cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Anti-BCMA CAR T cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Anti-BCMA CAR T cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hrain Biotechnology Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Preclinical[1]
Company: HHrain Biotechnology Co., Ltd.

Anti-BCMA CAR T cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2030

Trials by Indication[1]

Multiple Myeloma3 trials

Multiple Myeloma, Refractory1 trial

References

Drug Info

Quick Facts

Related News